CAP方案联合艾迪注射液治疗晚期非小细胞肺癌的临床研究  

Clinical Study of CAP Regimen Combined with Aidi Injection in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：曹建中[1] 丁亚亭[1] 马剑波[2] 冯建军[1] 钱坤艳 CAO Jian-zhong;DING Ya-ting;MA Jian-bo;FENG Jian-jun;QIAN Kun-yan(Department of Pharmacy,Affiliated Hospital of Nantong University,Nantong,Jiangsu,226001,China;Department of Oncology,Affiliated Hospital of Nantong University,Nantong,Jiangsu,226001,China;Chongchuan District CDC Control Center,Nantong,Jiangsu,226006,China)

机构地区：[1]南通大学附属医院药学部,江苏南通226001 [2]南通大学附属医院肿瘤科,江苏南通226001 [3]南通市崇川区疾控中心,江苏南通226006

出　　处：《现代生物医学进展》2020年第19期3736-3739,共4页Progress in Modern Biomedicine

基　　金：江苏省重点研发计划项目(BE2019692);南通市民生科技重点项目(MS32018010)。

摘　　要：目的:研究CAP方案联合艾迪注射液治疗晚期非小细胞肺癌的效果。方法:选择2016年1月~2019年1月我院的81例晚期非小细胞肺癌患者,随机分为两组。对照组的41例晚期非小细胞肺癌患者采用CAP方案,即快速静脉滴注吡柔比星50 mg/m2和环磷酰胺600 mg/m^2,d1,顺铂80 mg/m^2,d2-d4,1个周期为28 d,共治疗2个周期。观察组的40例晚期非小细胞肺癌患者联合静脉滴注艾迪注射液,每次50 mL,每天1次,1个疗程为3 w,共治疗3个疗程。比较两组的免疫功能、生活质量和不良反应情况。结果:观察组的有效率明显高于对照组(P<0.05);观察组治疗后的CD4^+、CD3^+及CD4^+/CD8^+明显升高(P<0.05),且明显高于对照组(P<0.05);观察组的生活质量提高17例,稳定10例,降低6例,观察组的生活质量改善率为82.50%(33/40),明显高于对照组的53.66%(22/41)(P<0.05);观察组的消化道反应发生率明显低于对照组(P<0.05),两组的过敏反应、神经毒性和脱发发生率无明显差异(P>0.05)。结论:艾迪注射液联合CAP方案可以提高晚期非小细胞肺癌的化疗疗效以及生活质量,改善免疫功能,减轻化疗所致的不良反应。Objective:To study the effect of CAP regimen combined with Aidi injection in the treatment of advanced non-small cell lung cancer.Methods:Selected 81 cases of patients with advanced non-small cell lung cancer who were treated in our hospital from January 2016 to January 2019,divided into two groups randomly.In the control group,41 patients with advanced non-small cell lung cancer were treated with CAP regimen,rapid intravenous drip of pirarubicin 50 mg/m^2 and cyclophosphamide 600 mg/m^2,d1,cisplatin 80 mg/m^2,d2-d4,a cycle of 28 days,a total of 2 cycles.The observation group of 40 patients with advanced non-small cell lung cancer combined with intravenous drip of Aidi injection,50 mL each time,once a day,a course of 3 weeks,a total of three courses of treatment.The immune function,quality of life and adverse reactions were compared between the two groups.Results:The effective rate of the observation group was significantly higher than control group(P<0.05).After treatment,the levels of CD4^+,CD3^+,CD4^+/CD8^+in the observation group were significantly higher than those in the control group(P<0.05).The quality of life in the observation group was improved in 17 cases,stabilized in 10 cases and decreased in 6 cases.The improvement rate of the quality of life in the observation group was 82.50%(33/40),which was significantly higher than that in the control group(53.66%(22/41)(P<0.05)).The incidence of digestive tract reaction in the observation group was significantly lower than that in the control group(P<0.05).There was no significant difference in the incidence of allergic reaction,neurotoxicity and alopecia between the two groups(P>0.05).Conclusion:Aidi injection combined with CAP regimen can improve the efficacy and quality of life of patients with advanced non-small cell lung cancer,improve immune function and alleviate adverse reactions caused by chemotherapy.

关 键 词：艾迪注射液 CAP方案 非小细胞肺癌 免疫功能 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]